what is the future of cart-ddbcma?
Published 11 months ago • 137 plays • Length 3:15Download video MP4
Download video MP3
Similar videos
-
4:34
what is the future for car-t in multiple myeloma?
-
6:52
who is the right patient for car-t therapy?
-
0:59
phase i study of cart-ddbcma in r/r multiple myeloma
-
5:19
bcma-targeted car-ts and their role in late-relapse multiple myeloma
-
3:47
what is car t-cell therapy?
-
4:12
is there an ideal space for allogeneic car-t products for myeloma?
-
6:00
future of bcma-targeting car-t for myeloma
-
3:03
the future of car-t therapy for multiple myeloma
-
8:14
bispecific versus car t-cell therapy for myeloma and bridging therapy needs for car-t
-
3:35
the future of anti-bcma car t-cell therapy in myeloma
-
9:16
frontline car-t use and the “sweet spot” for treatment sequencing
-
7:58
new and novel agents for dlbcl: bispecifics, car-t, and more
-
3:18
phase i study of cart-ddbcma in r/r multiple myeloma
-
21:41
the future in multiple myeloma: bite immunotherapy, car-t, and immune checkpoint inhibitors
-
9:39
what are dual car-t cells?
-
3:18
which patients are not well suited for car-t therapy?
-
2:43
where does car-t fit in the myeloma treatment algorithm?
-
1:13
the future of car t-cells and bispecific antibodies to treat myeloma
-
2:12
what is car-t cell persistence?